Clopidogrel

Evidence Level: L5

Predicted Indications: 7

Clopidogrel

Pharmacist Assessment Report

Clopidogrel: From Acute Coronary Syndrome to Migraine with Brainstem Aura

One-Sentence Summary

Clopidogrel is an antiplatelet drug originally used for acute coronary syndrome, intracranial embolism and ST-elevation myocardial infarction. The TxGNN model predicts it may be effective for migraine with brainstem aura. No clinical trials are registered for this exact condition, but 16 publications support the direction, mostly in the wider group of patients with migraine with aura and a right-to-left shunt (such as a patent foramen ovale, PFO).

Quick Overview

Item	Content
Original Indication	Acute coronary syndrome, intracranial embolism, ST-elevation myocardial infarction
Predicted New Indication	Migraine with brainstem aura
TxGNN Prediction Score	0.9944
Evidence Level	L5 (one pilot RCT, observational studies and a systematic review; no completed Phase 2/3 trial for this exact condition)
Canada Market Status	Marketed (marketed DINs: 19 of 19)
Number of DINs	19 (marketed: 19)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Clopidogrel is known to be a P2Y12 platelet inhibitor. Its efficacy in preventing thrombotic events in acute coronary syndrome and ischaemic cerebrovascular disease is established.

Migraine with aura, including brainstem aura, is thought to involve tiny emboli or platelet-derived vasoactive substances (such as serotonin) that pass through a right-to-left shunt like a PFO. Blocking platelet aggregation could reduce the release of these triggers. This gives a plausible link between clopidogrel’s antiplatelet action and migraine prevention.

Most of the supporting evidence comes from the broader migraine-with-aura and PFO population, not from brainstem aura specifically. The closely related broader indication “migraine disorder” (the second-ranked prediction, score 0.9944) has more direct support. It includes a completed Phase 4 trial of clopidogrel added to aspirin after atrial septal defect closure (CANOA, n=220, NCT00799045), published in JAMA, and a 2026 multicentre randomised trial of antithrombotic treatment in migraine with PFO (BMJ, PMID 42526943). These do not prove efficacy in brainstem aura, but they make the broader migraine direction credible.

Clinical Trial Evidence

Currently no related clinical trials registered for migraine with brainstem aura.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24836213	2014	Pilot RCT	Cephalalgia	Pilot randomised trial testing clopidogrel as migraine prevention, prompted by anecdotal reports
39989443	2025	Systematic review	Headache	Reviews the evidence on antithrombotic drugs as migraine preventives
32848048	2020	Cohort	J Investig Med	Clopidogrel 75 mg/day added to existing prevention for drug-refractory migraine with PFO, followed at 3 and 6 months
30478066	2018	Retrospective review	Neurology	Off-label thienopyridine (including clopidogrel) use in migraine patients with PFO
30478067	2018	Open-label pilot	Neurology	Ticagrelor (a related P2Y12 inhibitor) in refractory migraine with PFO, following reports that clopidogrel and prasugrel reduced symptoms
24770421	2014	Retrospective review	Cephalalgia	Clopidogrel as primary therapy in migraineurs with right-to-left shunt
16103551	2005	Cohort	Heart	Clopidogrel reduced migraine with aura after transcatheter closure of PFO and atrial septal defects
26908949	2016	RCT (device, not drug)	Eur Heart J	PRIMA trial of PFO closure in medically refractory migraine with aura; indirect relevance
22992406	2012	Case report	Cephalalgia	New migraine after atrial septal defect closure responded to ticlopidine, an analogue of clopidogrel
15966922	2005	Case series	J Interv Cardiol	Severe migraine after atrial septal defect closure in 5 of 13 patients, with rapid relief after clopidogrel 300 mg

Canada Market Information

Clopidogrel has 19 valid single-ingredient authorisations in Canada. The main ones are listed below.

DIN	Product Name
02238682	PLAVIX
02252767	APO-CLOPIDOGREL
02293161	TEVA-CLOPIDOGREL
02348004	PMS-CLOPIDOGREL
02379813	TARO-CLOPIDOGREL

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not label text): acute liver failure, hepatitis, blood coagulation disease, injury, thrombocytopenic purpura, active peptic ulcer disease, intracranial haemorrhage.
Drug Interactions: 100 interactions were recorded. The main major interactions are with:
- proton pump inhibitors: omeprazole, esomeprazole, rabeprazole
- pioglitazone
- repaglinide
- loperamide
Moderate interactions include acetylsalicylic acid, morphine, bupropion, cimetidine, clarithromycin, lansoprazole and pantoprazole.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is high and the mechanism is plausible, but no trial has tested clopidogrel in brainstem aura specifically. The existing evidence is mostly small or observational and comes from migraine with aura and PFO more broadly. Results are mixed or modest, and the antiplatelet bleeding risk must be weighed against a non-fatal condition. The broader “migraine disorder” indication is the better-supported research question.

To proceed, the following is needed:

Pooled effect sizes from the 2025 systematic review and the 2026 BMJ randomised trial (PMID 42526943), to see whether clopidogrel benefit holds up and whether it extends to brainstem aura
Subgroup data on patients with brainstem aura, with or without a right-to-left shunt
Mechanism of action data
Health Canada package insert warnings and contraindications
A bleeding-risk and drug-interaction assessment (especially with proton pump inhibitors) for a migraine population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.